NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

低纖維蛋白原血症:市場分析,流行病學,到2030年的市場預測

Hypofibrinogenemia - Market Insights, Epidemiology, and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 955306
出版日期 按訂單生產 內容資訊 英文 127 Pages
商品交期: 10個工作天內
價格
低纖維蛋白原血症:市場分析,流行病學,到2030年的市場預測 Hypofibrinogenemia - Market Insights, Epidemiology, and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 127 Pages
簡介
低纖維蛋白原血症是一種罕見的疾病,其特徵是纖維蛋白原水平降低(低於1.5 g/L),血漿纖維蛋白原水平從1.5 g/L降至4.5 g/L。它大致分為先天性低纖維蛋白原性血症和後天性低纖維蛋白原性血症。纖維蛋白原是血凝塊形成的重要蛋白質,並提供了血凝塊強度必不可少的基質和網狀網絡。維持纖維蛋白原水平是一項基本的治療目標,尤其是對於圍手術期出血的患者。低纖維蛋白原水平與血栓形成減少有關,並與嚴重出血密切相關。先天性纖維蛋白原疾病是由三個纖維蛋白原基因內發生的基因突變引起的,而獲得性低纖維蛋白原血症則是嚴重的肝臟疾病或瀰散性血管內凝血綜合徵(DIC),心臟外科手術等。是造成的。

本報告概述了到2030年美國,德國,法國,意大利,西班牙,英國和日本的七個主要國家中的低纖維蛋白原血症的流行情況。它提供有關特定國家的流行病,當前的治療方法,未解決的需求,上市的治療方法,新的治療方法,市場前景等信息。

目錄

第1章主要調查結果

第2章市場概述

  • 2017年市場佔有率
  • 2030年的市場佔有率

第3章執行摘要

第4章組織

第5章疾病概述

  • 簡介
  • 分類
  • 體徵和症狀
  • 病因
  • 診斷
    • 鑑別診斷
    • 產前診斷

第6章流行病學和患者人群

  • 主要發現
  • 7個主要國家的病例數

第7章國家流行病學

  • 假設和依據
  • 主要專家意見:流行病學
  • 美國
    • 案件數
    • 特定類型的案例
    • 獲得性低纖維蛋白原血症的病例
  • 德國
  • 法國
  • 意大利
  • 西班牙
  • 英國
  • 日本

第8章當前處理方法

第9章不受支持的需求

第10章市場上的藥物

  • RiaSTAP:CSL Behring
  • Fibryna:Octapharma
  • FibCLOT(Clottafact):LFB Biomedicaments

第11章新療法

  • BT524:Biotest

第12章市場前景

  • 主要發現
  • 7個主要國家/地區的市場規模

第13章按國家劃分的市場前景

  • 專家觀點:市場
  • 美國市場規模
  • 德國市場規模
  • 法國市場規模
  • 意大利市場規模
  • 西班牙市場規模
  • 英國市場規模
  • 日本市場規模

第14章市場增長的推動者

第15章市場壁壘

第16章市場准入和贖回

第17章SWOT分析

第18章案例研究

  • 案例研究:低纖維蛋白原血症(2例報告)
  • 案例研究:低纖維蛋白原血症患者通過產前和圍產期管理成功分娩
  • 病例報告:Vincristine和Prednisone聯合治療淋巴細胞性白血病

第19章參考

第20章附錄

  • 調查方法

第21章Delve Insight服務內容

第22章免責聲明

關於第23章Delve Insight

目錄
Product Code: DIMI0967

DelveInsight's 'Hypofibrinogenemia - Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the Hypofibrinogenemia, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Hypofibrinogenemia market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Hypofibrinogenemia market size from 2017 to 2030 segmented by seven major markets. The Report also covers current Hypofibrinogenemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Hypofibrinogenemia: Disease Understanding and Treatment Algorithm

Hypofibrinogenemia Overview

Hypofibrinogenemia is a rare disorder characterized by low fibrinogen levels (<1.5 g/L), normal plasma fibrinogen levels ranging from 1.5 g/L to 4.5 g/L. It is broadly classified into two types, i.e., Congenital Hypofibrinogenemia and Acquired Hypofibrinogenemia.

Fibrinogen is a critical protein for clot formation, providing a matrix and mesh network essential for clot strength. Maintaining fibrinogen levels is an essential therapeutic target in bleeding patients, particularly in perioperative settings. Low fibrinogen levels are associated with reduced clot strength and are strongly associated with severe bleeding.

Congenital fibrinogen disorders are caused by genetic variants occurring within all three fibrinogen genes. However, each gene (FGA, FGB, FGG) differently shows specific variants, wherein "nonsense" variants are mostly found within FGA, while FGG variants are prevalently responsible for missense changes.

In congenital hypofibrinogenemia, genes responsible for producing fibrinogen (a critical blood clotting factor) are unable to make a functional fibrinogen glycoprotein because of an inherited mutation. In contrast, acquired hypofibrinogenemia can result from either severe hepatic disease or disseminated intravascular coagulation (DIC), cardiac surgery, etc.

Several genetic variants have been identified in individuals with fibrinogen disorders. The complexity of the fibrinogen molecules, formed by three non-identical chains and with a trinodal organization, renders the identification of molecular causes and clinical and biochemical phenotypes very challenging. However, the acknowledgment of the type of molecular defect is crucial for a safer therapy as it can help improve the clinical management of patients.

Hypofibrinogenemia Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Hypofibrinogenemia market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Hypofibrinogenemia market report gives a thorough understanding of Hypofibrinogenemia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Hypofibrinogenemia treatment algorithms and treatment guidelines for Hypofibrinogenemia in the US, Europe, and Japan.

Hypofibrinogenemia Epidemiology

Hypofibrinogenemia epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Hypofibrinogenemia epidemiology segmented as the Total Cases of Hypofibrinogenemia, Type-Specific Cases of Hypofibrinogenemia (as congenital and acquired), and Acquired Hypofibrinogenemia cases. The report includes the prevalent scenario of Hypofibrinogenemia in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Hypofibrinogenemia Epidemiology

The epidemiology segment also provides the Hypofibrinogenemia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total prevalent population of Hypofibrinogenemia in 7MM countries was estimated to be 11,084 cases in 2017.

Hypofibrinogenemia Drug Chapters

The drug chapter segment of the Hypofibrinogenemia report encloses the detailed analysis of Hypofibrinogenemia marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Hypofibrinogenemia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Fibrinogen replacement therapy is currently indicated as prophylaxis and therapy of hemorrhage in congenital and acquired fibrinogen deficiency, the latter being associated with liver failure, disseminated intravascular coagulation, massive transfusion, and cardiac surgery. Fibrinogen supplementation can be provided by transfusion of fresh-frozen plasma (FFP), cryoprecipitate, and fibrinogen concentrate.

Products detail in the report…

Hypofibrinogenemia Emerging Drugs

BT-524 (Biotest)

A novel fibrinogen concentrate purified from human plasma developed by Biotest. The company investigated the product clinically in a multinational phase I/III trial in patients with congenital fibrinogen deficiency and for the acquired fibrinogen deficiency. Biotest is conducting a phase III study in multiple European countries in patients with high blood loss during spine surgery. The results of both studies will serve as a basis for the marketing authorization of fibrinogen concentrate BT524 for the treatment of patients with congenital and acquired fibrinogen deficiency.

Products detail in the report…

Hypofibrinogenemia Market Outlook

The Hypofibrinogenemia market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Hypofibrinogenemia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Hypofibrinogenemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Hypofibrinogenemia market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Hypofibrinogenemia market in 7MM. The market size of Hypofibrinogenemia in the seven major markets was found to be USD 161.5 Million in 2017.

The United States Market Outlook

This section provides a total of Hypofibrinogenemia market size and market size by therapies in the United States.

The United States accounts for the highest market size of Hypofibrinogenemia in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Fresh frozen plasma also contains fibrinogen and is available in all hospital settings and is comparatively cheap but requires the administration of large quantities of fluid to achieve a reasonable fibrinogen dose. Although, FFP has several limitations including a low fibrinogen content, which means that large volumes must be given, and the risk of transfusion-related complications (e.g., transfusion-related acute lung injury [TRALI] and viral transmission), cryoprecipitate and fibrinogen concentrate has the major role.

Fibrinogen concentrate preparation includes safety steps for inactivation/removal of viruses, so concentrates are safer than cryoprecipitate or FFP. Furthermore, more precise dosing can be accomplished with fibrinogen concentrates because their potency is known, in contrast to FFP or cryoprecipitates. However, these products are still useful when no concentrates are available. Fibrinogen concentrates available for the treatment of Hypofibrinogenemia include Clottafact from LFB, RiaStap (CSL Behring), Fibryna (Octapharma).

EU-5 Countries: Market Outlook

Cryoprecipitate appear to be more cost-effective in the UK. The cost advantage, however, is lost in patients born after January 1996, as the national recommendation is to use methylene blue-treated non-UK-plasma products. Particularly, before these patients constitute the majority of blood recipients, it is a major challenge to keep sufficient stock of MB-treated cryoprecipitate of the optimal blood group without causing wastage due to expiry, and there is a stringent requirement to infuse this within 4 h of thawing. MF plasma products are approximately 5× as expensive as UK-based plasma products. Also, although cryoprecipitate is cheaper than fibrinogen concentrate, a recent cost-effective analysis showed that the overall costs (i.e., including compatibility testing, thawing, and administration) of cryoprecipitate and fibrinogen concentrate are quite similar.

Japan Market Outlook

The total of Hypofibrinogenemia market size and market size by therapies in Japan are also mentioned.

Hypofibrinogenemia Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers Hypofibrinogenemia market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Hypofibrinogenemia Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Hypofibrinogenemia key players involved in developing targeted therapeutics.

BT-524 (Biotest) is the only emerging therapy in the developmental phase for the treatment of Congenital and Acquired Hypofibrinogenemia.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Hypofibrinogenemia emerging therapies.

Reimbursement Scenario in Hypofibrinogenemia

Cryoprecipitate preparation is the only available source of fibrinogen for therapeutic purposes in some countries. Despite increasing interest in the use of fibrinogen concentrates, cryoprecipitate remains the major source of fibrinogen in England. In the UK, the cryoprecipitate is provided as single units of standard cryoprecipitate or methylene-blue (MB)-treated non-UK sourced cryoprecipitate or pools of 5 units.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Hypofibrinogenemia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or the Hypofibrinogenemia market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive & Market Intelligence analysis of the Hypofibrinogenemia Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Hypofibrinogenemia, explaining its causes, signs and symptoms, pathophysiology and currently available therapies
  • Comprehensive insight has been provided into the Hypofibrinogenemia epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Hypofibrinogenemia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Hypofibrinogenemia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hypofibrinogenemia market

Report Highlights:

  • In the coming years, Hypofibrinogenemia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Hypofibrinogenemia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Hypofibrinogenemia. Launch of emerging therapies will significantly impact the Hypofibrinogenemia market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Hypofibrinogenemia.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Hypofibrinogenemia Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Hypofibrinogenemia Pipeline Analysis
  • Hypofibrinogenemia Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Hypofibrinogenemia Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Hypofibrinogenemia Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Hypofibrinogenemia Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What were the Hypofibrinogenemia Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Hypofibrinogenemia total market Size as well as market Size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings of the market across 7MM and which country will have the largest Hypofibrinogenemia market Size during the forecast period (2017-2030)?
  • At what CAGR, the Hypofibrinogenemia market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Hypofibrinogenemia market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Hypofibrinogenemia market growth till 2030 and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of the Hypofibrinogenemia?
  • What is the historical Hypofibrinogenemia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What would be the forecasted patient pool of Hypofibrinogenemia in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Hypofibrinogenemia?
  • Out of all 7MM countries, which country would have the highest prevalent population of Hypofibrinogenemia during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Hypofibrinogenemia?
  • What are the current treatment guidelines for the treatment of Hypofibrinogenemia in the USA, Europe, and Japan?
  • What are the Hypofibrinogenemia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Hypofibrinogenemia?
  • How many therapies are developed by each company for the treatment of Hypofibrinogenemia?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Hypofibrinogenemia?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hypofibrinogenemia therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Hypofibrinogenemia and their status?
  • What are the key designations that have been granted for the emerging therapies for Hypofibrinogenemia?
  • What are the global historical and forecasted market of Hypofibrinogenemia?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Hypofibrinogenemia market
  • To understand the future market competition in the Hypofibrinogenemia market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Hypofibrinogenemia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Hypofibrinogenemia market
  • To understand the future market competition in the Hypofibrinogenemia market

Table of Contents

1. Key Insights

2. Hypofibrinogenemia: Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Hypofibrinogenemia in 2017
  • 2.2. Market Share (%) Distribution of Hypofibrinogenemia in 2030

3. Executive summary

4. Organizations

5. Disease Overview: Hypofibrinogenemia

  • 5.1. Introduction
  • 5.2. Classification
  • 5.3. Signs and Symptoms
  • 5.4. Pathogenesis
  • 5.5. Diagnosis
    • 5.5.1. Differential Diagnosis
    • 5.5.2. Prenatal Diagnosis

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. 7MM Total cases of Hypofibrinogenemia

7. Country Wise-Epidemiology of Hypofibrinogenemia

  • 7.1. Assumptions and Rationale
  • 7.2. KOL Views: Epidemiology
  • 7.3. United States
    • 7.3.1. Total Cases of Hypofibrinogenemia in the United States
    • 7.3.2. Type-Specific Cases of Hypofibrinogenemia in the US
    • 7.3.3. Acquired Hypofibrinogenemia cases in the US
  • 7.4. Germany
    • 7.4.1. Total Cases of Hypofibrinogenemia in Germany
    • 7.4.2. Type-Specific Cases of Hypofibrinogenemia in Germany
    • 7.4.3. Acquired Hypofibrinogenemia cases in Germany
  • 7.5. France
    • 7.5.1. Total Cases of Hypofibrinogenemia in France
    • 7.5.2. Type-Specific Cases of Hypofibrinogenemia in France
    • 7.5.3. Acquired Hypofibrinogenemia cases in France
  • 7.6. Italy
    • 7.6.1. Total Cases of Hypofibrinogenemia in Italy
    • 7.6.2. Type-Specific Cases of Hypofibrinogenemia in Italy
    • 7.6.3. Acquired Hypofibrinogenemia cases in Italy
  • 7.7. Spain
    • 7.7.1. Total Cases of Hypofibrinogenemia in Spain
    • 7.7.2. Type-Specific Cases of Hypofibrinogenemia in Spain
    • 7.7.3. Acquired Hypofibrinogenemia cases in the Spain
  • 7.8. United Kingdom
    • 7.8.1. Total Cases of Hypofibrinogenemia in the UK
    • 7.8.2. Type-Specific Cases of Hypofibrinogenemia in the UK
    • 7.8.3. Acquired Hypofibrinogenemia cases in the UK
  • 7.9. Japan
    • 7.9.1. Total Cases of Hypofibrinogenemia in Japan
    • 7.9.2. Type-Specific Cases of Hypofibrinogenemia in Japan
    • 7.9.3. Acquired Hypofibrinogenemia cases in the Japan

8. Current Treatment Practices

9. Unmet needs

10. Marketed therapies

  • 10.1. RiaSTAP: CSL Behring
    • 10.1.1. Product Description
    • 10.1.2. Regulatory Milestones
    • 10.1.3. Other Development Activities
    • 10.1.4. Clinical Development
    • 10.1.5. Safety and Efficacy
    • 10.1.6. Product Profile
  • 10.2. Fibryna: Octapharma
    • 10.2.1. Product Description
    • 10.2.2. Regulatory Milestones
    • 10.2.3. Clinical Development
    • 10.2.4. Safety and Efficacy
    • 10.2.5. Product Profile
  • 10.3. FibCLOT (Clottafact): LFB Biomedicaments
    • 10.3.1. Product Description
    • 10.3.2. Regulatory Milestones
    • 10.3.3. Clinical Development
    • 10.3.4. Safety and Efficacy
    • 10.3.5. Product Profile

11. Emerging Therapies

  • 11.1. BT524: Biotest
    • 11.1.1. Drug Description
    • 11.1.2. Other Developmental Activities
    • 11.1.3. Clinical Development
    • 11.1.4. Safety and Efficacy
    • 11.1.5. Product Profile

12. Hypofibrinogenemia: Market Outlook

  • 12.1. Key Findings
  • 12.2. Market Size of Hypofibrinogenemia in 7MM

13. Market Outlook by Country

  • 13.1. KOL views: Market
  • 13.2. United States Market Size
    • 13.2.1. The total market size of Hypofibrinogenemia in the US
    • 13.2.2. Therapy Based Market Size of Congenital Hypofibrinogenemia in the US
    • 13.2.3. Therapy Based Market Size of Acquired Hypofibrinogenemia in the US
  • 13.3. Germany Market Size
    • 13.3.1. The total market size of Hypofibrinogenemia in Germany
    • 13.3.2. Therapy Based Market Size of Congenital Hypofibrinogenemia in Germany
    • 13.3.3. Therapy Based Market Size of Acquired Hypofibrinogenemia in Germany
  • 13.4. France Market Size
    • 13.4.1. The total market size of Hypofibrinogenemia in France
    • 13.4.2. Therapy Based Market Size of Congenital Hypofibrinogenemia in France
    • 13.4.3. Therapy Based Market Size of Acquired Hypofibrinogenemia in France
  • 13.5. Italy Market Size
    • 13.5.1. The total market size of Hypofibrinogenemia in Italy
    • 13.5.2. Therapy Based Market Size of Congenital Hypofibrinogenemia in Italy
    • 13.5.3. Therapy Based Market Size of Acquired Hypofibrinogenemia in Italy
  • 13.6. Spain Market Size
    • 13.6.1. The total market size of Hypofibrinogenemia in Spain
    • 13.6.2. Therapy Based Market Size of Congenital Hypofibrinogenemia in Spain
    • 13.6.3. Therapy Based Market Size of Acquired Hypofibrinogenemia in Spain
  • 13.7. UK Market Size
    • 13.7.1. The total market size of Hypofibrinogenemia in the UK
    • 13.7.2. Therapy Based Market Size of Congenital Hypofibrinogenemia in the UK
    • 13.7.3. Therapy Based Market Size of Acquired Hypofibrinogenemia in the UK
  • 13.8. Japan Market Size
    • 13.8.1. The total Market size of Hypofibrinogenemia in Japan
    • 13.8.2. Therapy Based Market Size of Congenital Hypofibrinogenemia in Japan
    • 13.8.3. Therapy Based Market Size of Acquired Hypofibrinogenemia in Japan

14. Market Drivers

15. Market Barriers

16. Market access and Reimbursement

17. SWOT Analysis

18. Case studies

  • 18.1. Case study: Hypofibrinogenemia (A Report of Two Cases)
  • 18.2. Case study: Prenatal and Peripartum Management of Patients with Hypofibrinogenemia Resulted in Two Successful Deliveries
  • 18.3. Case Report: Hypofibrinogenemia Associated with Vincristine and Prednisone Therapy in Lymphoblastic Leukemia

19. Bibliography

20. Appendix

  • 20.1. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1: Causes of Acquired Hypofibrinogenemia
  • Table 2: Classification of Hypofibrinogenemia based on levels of functional fibrinogen
  • Figure 3: Schematic structure of the fibrinogen molecule
  • Figure 4: Schematic structure of the fibrinogen molecule
  • Figure 5: Schematic conversion of fibrinogen molecule to active fibrin
  • Table 6: Common mutations associated with hypofibrinogenemia
  • Table 7: Hypofibrinogenemia Mutations associated with liver damage
  • Table 8: Laboratory Assays in congenital fibrinogen deficiencies
  • Table 9: Laboratory diagnosis results for hypofibrinogenemia.
  • Table 10: Total cases of Hypofibrinogenemia in USD Million (2017-2030)
  • Table 11: Total Cases of Hypofibrinogenemia in the US (2017-2030)
  • Table 12: Type-specific Cases of Hypofibrinogenemia in the US (2017-2030)
  • Table 13: Acquired Hypofibrinogenemia cases in the US (2017-2030)
  • Table 14: Total Cases of Hypofibrinogenemia in Germany (2017-2030)
  • Table 15: Type-specific Cases of Hypofibrinogenemia in Germany (2017-2030)
  • Table 16: Acquired Hypofibrinogenemia cases in Germany (2017-2030)
  • Table 17: Total Cases of Hypofibrinogenemia in France (2017-2030)
  • Table 18: Type-specific Cases of Hypofibrinogenemia in France (2017-2030)
  • Table 19: Acquired Hypofibrinogenemia cases in France (2017-2030)
  • Table 20: Total Cases of Hypofibrinogenemia in Italy (2017-2030)
  • Table 21: Type-specific Cases of Hypofibrinogenemia in Italy (2017-2030)
  • Table 22: Acquired Hypofibrinogenemia cases in Italy (2017-2030)
  • Table 23: Total Cases of Hypofibrinogenemia in Spain (2017-2030)
  • Table 24: Type-specific Cases of Hypofibrinogenemia in Spain (2017-2030)
  • Table 25: Acquired Hypofibrinogenemia cases in Spain (2017-2030)
  • Table 26: Total Cases of Hypofibrinogenemia in the UK (2017-2030)
  • Table 27: Type-specific Cases of Hypofibrinogenemia in the UK (2017-2030)
  • Table 28: Acquired Hypofibrinogenemia cases in the UK (2017-2030)
  • Table 29: Total Cases of Hypofibrinogenemia in Japan (2017-2030)
  • Table 30: Type-specific Cases of Hypofibrinogenemia in Japan (2017-2030)
  • Table 31: Acquired Hypofibrinogenemia cases in Japan (2017-2030)
  • Table 32: Comparison between Cryoprecipitate and fibrinogen concentrate as replacement therapy
  • Table 33: Fibrinogen concentrate available in market
  • Table 34: RiaSTAP, Clinical Trial Description, 2020
  • Table 35: Fibryna, Clinical Trial Description, 2020
  • Table 36: FibCLOT, Clinical Trial Description, 2020
  • Table 37: BT524, Clinical Trial Description, 2020
  • Table 38: 7 Major Market Size of Hypofibrinogenemia in USD Million (2017-2030)
  • Table 39: US Market Size of Hypofibrinogenemia in USD Million (2017-2030)
  • Table 40: Therapy Based Market Size of Congenital Hypofibrinogenemia in the US in USD Million (2017-2030)
  • Table 41: Therapy Based Market Size of Acquired Hypofibrinogenemia in the US in USD Million (2017-2030)
  • Table 42: Germany Market Size of Hypofibrinogenemia in USD Million (2017-2030)
  • Table 43: Therapy Based Market Size of Congenital Hypofibrinogenemia in Germany in USD Million (2017-2030)
  • Table 44: Therapy Based Market Size of Acquired Hypofibrinogenemia in Germany in USD Million (2017-2030)
  • Table 45: France Market Size of Hypofibrinogenemia in USD Million (2017-2030)
  • Table 46: Therapy Based Market Size of Congenital Hypofibrinogenemia in France in USD Million (2017-2030)
  • Table 47: Therapy Based Market Size of Acquired Hypofibrinogenemia in France in USD Million (2017-2030)
  • Table 48: Italy Market Size of Hypofibrinogenemia in USD Million (2017-2030)
  • Table 49: Therapy Based Market Size of Congenital Hypofibrinogenemia in Italy in USD Million (2017-2030)
  • Table 50: Therapy Based Market Size of Acquired Hypofibrinogenemia in Italy in USD Million (2017-2030)
  • Table 51: Spain Market Size of Hypofibrinogenemia in USD Million (2017-2030)
  • Table 52: Therapy Based Market Size of Congenital Hypofibrinogenemia in Spain in USD Million (2017-2030)
  • Table 53: Therapy Based Market Size of Acquired Hypofibrinogenemia in Spain in USD Million (2017-2030)
  • Table 54: UK Market Size of Hypofibrinogenemia in USD Million (2017-2030)
  • Table 55: Therapy Based Market Size of Congenital Hypofibrinogenemia in the UK in USD Million (2017-2030)
  • Table 56: Therapy Based Market Size of Acquired Hypofibrinogenemia in the UK in USD Million (2017-2030)
  • Table 57: Japan Market Size of Hypofibrinogenemia in USD Million (2017-2030)
  • Table 58: Therapy Based Market Size of Congenital Hypofibrinogenemia in Japan in USD Million (2017-2030)
  • Table 59:Therapy Based Market Size of Acquired Hypofibrinogenemia in Japan in USD Million (2017-2030)

List of Figures

  • Figure 1: Total Cases of Hypofibrinogenemia in 7MM (2017-2030)
  • Figure 2: Total Cases of Hypofibrinogenemia in the United States (2017-2030)
  • Figure 3: Type-specific Cases of Hypofibrinogenemia in the US (2017-2030)
  • Figure 4: Acquired Hypofibrinogenemia cases in the US (2017-2030)
  • Figure 5: Total Cases of Hypofibrinogenemia in Germany (2017-2030)
  • Figure 6: Type-specific Cases of Hypofibrinogenemia in Germany (2017-2030)
  • Figure 7: Acquired Hypofibrinogenemia cases in the Germany (2017-2030)
  • Figure 8: Total Cases of Hypofibrinogenemia in France (2017-2030)
  • Figure 9: Type-specific Cases of Hypofibrinogenemia in France (2017-2030)
  • Figure 10: Acquired Hypofibrinogenemia cases in France (2017-2030)
  • Figure 11: Total Cases of Hypofibrinogenemia in Italy (2017-2030)
  • Figure 12: Type-specific Cases of Hypofibrinogenemia in Italy (2017-2030)
  • Figure 13: Acquired Hypofibrinogenemia cases in Italy (2017-2030)
  • Figure 14: Total Cases of Hypofibrinogenemia in Spain (2017-2030)
  • Figure 15: Type-specific Diagnosed Prevalent Cases of Hypofibrinogenemia in Spain (2017-2030)
  • Figure 16: Acquired Hypofibrinogenemia cases in Spain (2017-2030)
  • Figure 17: Total Cases of Hypofibrinogenemia in the UK (2017-2030)
  • Figure 18: Type-specific Cases of Hypofibrinogenemia in the UK (2017-2030)
  • Figure 19: Acquired Hypofibrinogenemia cases in the UK (2017-2030)
  • Figure 20: Total Cases of Hypofibrinogenemia in the Japan (2017-2030)
  • Figure 21: Type-specific Cases of Hypofibrinogenemia in Japan (2017-2030)
  • Figure 22: Acquired Hypofibrinogenemia cases in Japan (2017-2030)
  • Figure 23: Unmet Needs of Hypofibrinogenemia
  • Figure 24: 7 Major Market Size of Hypofibrinogenemia in USD Million (2017-2030)
  • Figure 25: Market Size of Hypofibrinogenemia in the US, USD Millions (2017-2030)
  • Figure 26: Therapy Based Market Size of Congenital Hypofibrinogenemia in the US in USD Million (2017-2030)
  • Figure 27: Therapy Based Market Size of Acquired Hypofibrinogenemia in the US in USD Million (2017-2030)
  • Figure 28: Market Size of Hypofibrinogenemia in Germany, USD Millions (2017-2030)
  • Figure 29: Therapy Based Market Size of Congenital Hypofibrinogenemia in Germany in USD Million (2017-2030)
  • Figure 30: Therapy Based Market Size of Acquired Hypofibrinogenemia in Germany in USD Million (2017-2030)
  • Figure 31: Market Size of Hypofibrinogenemia in France, USD Millions (2017-2030)
  • Figure 32: Therapy Based Market Size of Congenital Hypofibrinogenemia in France in USD Million (2017-2030)
  • Figure 33: Therapy Based Market Size of Acquired Hypofibrinogenemia in France in USD Million (2017-2030)
  • Figure 34: Market Size of Hypofibrinogenemia in Italy, USD Millions (2017-2030)
  • Figure 35: Therapy Based Market Size of Congenital Hypofibrinogenemia in Italy in USD Million (2017-2030)
  • Figure 36: Therapy Based Market Size of Acquired Hypofibrinogenemia in Italy in USD Million (2017-2030)
  • Figure 37: Market Size of Hypofibrinogenemia in Spain, USD Millions (2017-2030)
  • Figure 38: Therapy Based Market Size of Congenital Hypofibrinogenemia in Spain in USD Million (2017-2030)
  • Figure 39: Therapy Based Market Size of Acquired Hypofibrinogenemia in Spain in USD Million (2017-2030)
  • Figure 40: Market Size of Hypofibrinogenemia in the UK, USD Millions (2017-2030)
  • Figure 41: Therapy Based Market Size of Congenital Hypofibrinogenemia in the UK in USD Million (2017-2030)
  • Figure 42: Therapy Based Market Size of Acquired Hypofibrinogenemia in the UK in USD Million (2017-2030)
  • Figure 43: Market Size of Hypofibrinogenemia in Japan, USD Millions (2017-2030)
  • Figure 44: Therapy Based Market Size of Congenital Hypofibrinogenemia in Japan in USD Million (2017-2030)
  • Figure 45: Therapy Based Market Size of Acquired Hypofibrinogenemia in Japan in USD Million (2017-2030)
  • Figure 46: Market Drivers
  • Figure 47:Market Barriers